CG Oncology, Inc. Common stock (CGON) Stock Forecast & Price Target
CG Oncology, Inc. Common stock · NASDAQ
$73.49+4.17 (+6.02%)
15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering CG Oncology, Inc. Common stock, 10 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $50.00 to $100.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $80.30 sits 9% above the current $73.49. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.68 next quarter toward $-2.75 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy1091%
Hold19%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to CG Oncology, Inc. Common stock.
As of Jul, 10 of 11 firms rate CGON a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CGON EPS & revenue forecast
EPS · NEXT QUARTER
$-0.68
Range $-0.77 – $-0.56 · 11 analysts · +19% YoY
Next period, 11 analysts expect CG Oncology, Inc. Common stock to earn $-0.68 a share (range $-0.77 – $-0.56), versus $-0.57 a year earlier. Full-year consensus is $-2.67, growing to $-2.75 the year after.
REVENUE · NEXT QUARTER
$563.1K
Range $0 – $2.0M · 11 analysts · -66% YoY
Revenue is expected to reach $563.1K (range $0 – $2.0M), -66.2% year-over-year. Full-year consensus is $11.8M, rising to $88.3M next year.
Top analysts covering CG Oncology, Inc. Common stock
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CGON.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #12
Buy
$79.00+7.5% to target
Overall win rate
61%
+ Follow
#2
Leonid Timashev
RBC Capital · Rank #69
Buy
$81.00+10.2% to target
Overall win rate
42%
+ Follow
#3
Josh Schimmer
Cantor Fitzgerald · Rank #140
Buy
$75.00+2.1% to target
Overall win rate
38%
+ Follow
#4
Gregory Renza
RBC Capital · Rank #179
Buy
$68.00-7.5% to target
Overall win rate
34%
+ Follow
#5
Andres Y. Maldonado
HC Wainwright & Co. · Rank #211
Buy
$100.00+36.1% to target
Overall win rate
38%
+ Follow
CGON stock forecast FAQ
What is CGON's average 12-month price target?+
The 10 analysts with a live target average $80.30 for CG Oncology, Inc. Common stock over the next 12 months, ranging from a $100.00 high to a $50.00 low.
Is CGON stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 10 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CGON?+
The Street-high target is $100.00 (HC Wainwright & Co.), and the Street-low is $50.00 (Jones Trading). The average of all 10 active targets is $80.30.
How many Wall Street analysts cover CGON?+
11 analysts have an active rating on CG Oncology, Inc. Common stock, and 10 firms carry a live 12-month price target.
Who is the most accurate analyst covering CGON?+
Among analysts who currently cover CGON, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #12). Their current call is Buy with a $79.00 target.
What is CG Oncology, Inc. Common stock's projected EPS for next quarter?+
The consensus estimate is $-0.68 per share (range $-0.77 – $-0.56) across 11 analysts. Full-year EPS is projected at $-2.67, rising to $-2.75 the following year.
How much revenue is CG Oncology, Inc. Common stock expected to report next quarter?+
Consensus revenue is $563.1K (range $0 – $2.0M). Full-year revenue is projected at $11.8M, growing to $88.3M next year.
Have analysts been upgrading or downgrading CGON lately?+
As of Jul, 10 of 11 firms rate CGON a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CGON calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
